Erasca, Inc. has reported promising preliminary results from its Phase 1 dose escalation trials for ERAS-0015, a pan-RAS molecular glue targeting RAS-mutant solid tumors. The data show 62% overall response rate (uORR) in patients with KRAS G12X non-small cell lung cancer (NSCLC) and 40% uORR in those with KRAS G12X pancreatic cancer (PDAC) at pharmacologically active doses (PADs) of 16-32 mg QD. Notably, in the post-ICI/platinum setting for NSCLC, the uORR reached 75%, highlighting the drug’s potential in heavily pre-treated populations.

The significance of these findings lies in the well-tolerated safety profile of ERAS-0015, characterized by low-grade adverse events and no dose-limiting toxicities (DLTs) reported to date. The pharmacokinetic (PK) data indicate a dose-dependent increase in exposure without an observed plateau, suggesting a favorable therapeutic window. Moreover, the drug demonstrated substantial reductions in circulating tumor DNA (ctDNA) for KRAS G12X, with all patients showing at least a 75% reduction at PAD doses, reinforcing its mechanism of action in inhibiting RAS signaling.

The implications for the field are substantial, particularly in the context of combination therapies. Preliminary data indicate that ERAS-0015 can be safely combined with standard doses of panitumumab, positioning it as a potential backbone therapy for future regimens. This positions ERAS-0015 not only as a promising monotherapy option but also as a candidate for synergistic combinations, potentially accelerating the development timelines for effective treatments in KRAS-driven malignancies. Upcoming data disclosures in H1 2027 will further clarify its role in the therapeutic landscape for these challenging cancers.

Source: globenewswire.com